NFKB1 and liver cancer: Interestingly, we recently reported that combination of celecoxib with the novel NF-κB inhibitor dehydroxymethyl-epoxyquinomicin (DHMEQ) synergistically inhibits cell growth, NF-κB p65 DNA-binding capacity, and cell proliferation in human HCC cells [195], providing a rational basis for the clinical use of this combination in the treatment of liver cancer.